BioSpace News Archive

AL Ideathon is an idea-sharing event designed to encourage creativity and innovation in the pharma, healthcare, and life sciences sectors. It provides a platform where participants can present their ideas to address real-world challenges faced by the industry. Last year, AL Ideathon received over 544 ideas, and prizes worth ₹10 lakhs were distributed to the winners. The event was a resounding success, with participants gaining recognition and many ideas being highlighted on our platform for their originality and relevance. The purpose of AL Ideathon is simple - great ideas should not remain on paper. By creating a space where professionals and innovators can collaborate. Whether it is a new approach to quality management, smarter use of digital systems, or ways to reduce manual effort in regulated environments, AL Ideathon values ideas that bring measurable impact. Building on the success of last year, this year’s AL Ideathon will be held on 27th September in Mumbai. The event once again invites professionals and innovators to share their perspectives on improving processes, compliance, efficiency, and patient outcomes. Every idea, whether simple or detailed, has the potential to spark meaningful discussions and inspire industry-wide conversations. Have an idea worth sharing? Submit your entry today and let your vision be heard at AL Ideathon 2025.

Our upcoming Employee Wellbeing Conference 2025 brings you everything that you need to know about Saudi Arabia’s focus on the latest initiatives that will help to transform your organisation’s wellbeing strategies

Kenneth E. Thorpe, PhD, is the Robert W. Woodruff Professor of Health Policy at Emory University and chair of the Partnership to Fight Chronic Disease (PFCD).

David Craig is CEO of Sarcomatrix Therapeutics, a biotechnology company developing small molecule therapies for muscle diseases. He previously held executive roles at Amgen, Gilead and Alexion, and advocates for pragmatic, multi-modal innovation in rare disease drug development.

VantAI will use its machine learning capabilities to identify novel target-effector pairs that Halda can use in designing its bifunctional small-molecule drugs.

Adaptive and Genentech first partnered in 2018 to advance T cell receptor-based therapies for cancer.

The FDA has postponed its decision date for Regenxbio’s Hunter syndrome gene therapy to review additional longer-term clinical data for the asset.

A new study in JAMA contradicts a series of statements made by HHS Secretary Robert F. Kennedy Jr. that paint vaccine advisory committees at the CDC and FDA as hopelessly corrupt.

Viking Therapeutics’ VK2735 achieves a 10.9% placebo-adjusted weight loss at 13 weeks, but a less than ideal safety profile marred the results.

The small molecule, vatiquinone, had already flunked a Phase III trial, but the company pushed ahead with an approval bid anyway.